Denali Therapeutics Inc (NASDAQ: DNLI) is 7.60% higher on its value in year-to-date trading and has touched a low of $14.56 and a high of $30.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DNLI stock was last observed hovering at around $21.65 in the last trading session, with the day’s gains setting it 1.44%.
Currently trading at $23.09, the stock is 6.26% and 14.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.99 million and changing 6.65% at the moment leaves the stock 18.95% off its SMA200. DNLI registered -20.46% loss for a year compared to 6-month gain of 16.97%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 9.85% loss in the last 1 month and extending the period to 3 months gives it a 25.35%, and is 8.40% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.96% over the week and 5.07% over the month.
Denali Therapeutics Inc (DNLI) has around 445 employees, a market worth around $3.29B and $295.39M in sales. Profit margin for the company is -46.46%. Distance from 52-week low is 58.59% and -25.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-9.16%).
The EPS is expected to shrink by -165.06% this year
The shares outstanding are 138.39M, and float is at 117.22M with Short Float at 6.34%.
Denali Therapeutics Inc (DNLI) Insider Activity
The most recent transaction is an insider sale by Krognes Steve E., the company’s Director. SEC filings show that Krognes Steve E. sold 30,000 shares of the company’s common stock on Jul 01 ’24 at a price of $22.12 per share for a total of $0.66 million. Following the sale, the insider now owns 34404.0 shares.
Denali Therapeutics Inc disclosed in a document filed with the SEC on Jul 01 ’24 that SATO VICKI L (Director) sold a total of 3,080 shares of the company’s common stock. The trade occurred on Jul 01 ’24 and was made at $22.14 per share for $68204.0. Following the transaction, the insider now directly holds 0.12 million shares of the DNLI stock.
Still, SEC filings show that on Jun 13 ’24, Krognes Steve E. (Director) disposed off 688 shares at an average price of $21.79 for $14992.0. The insider now directly holds 52,620 shares of Denali Therapeutics Inc (DNLI).
